| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4260229 | Transplantation Proceedings | 2010 | 5 Pages |
Abstract
Tacrolimus (Tac, FK506) is a widely used T-cell-targeted immunosuppression drug known as a calcineurin inhibitor. However, its pharmacologic effects on T-helper type 17 (Th17) cells have not been fully elucidated. Herein, we demonstrate that Tac inhibits Th17 cell differentiation and proliferation, and expression of IL-17 messenger RNA. The proposed mechanism is that Tac inhibits calcineurin and T-cell receptor stimulation-induced cell division. Because Th17 cells participate in allograft rejection, the results of the present study suggest a novel model of immunosuppression effects of Tac. In addition, they provide further implications for the therapeutic immunosuppression effects of Tac on allograft rejection.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
X.-J. Zhang, Y.-D. Kang, L. Xiao, R.-D. Li, G.-S. Ding, Z.-X. Wang, Z.-R. Fu,